Clinical Microbiology , University and Regional Laboratories , Region Skåne, Lund , Sweden ; Division of Infection Medicine, Department of Clinical Sciences , Lund University , Lund , Sweden.
Clinical Microbiology , University and Regional Laboratories , Region Skåne, Lund , Sweden.
Open Forum Infect Dis. 2014 May 23;1(1):ofu025. doi: 10.1093/ofid/ofu025. eCollection 2014 Mar.
Since Aerococcus sanguinicola was designated as a species in 2001, only a few cases of bacteremia have been reported. The aim with this study was to describe the clinical presentation of A sanguinicola bacteremia and to determine the antibiotic susceptibility and the capacity of the bacteria to form biofilm and to induce platelet aggregation.
Isolates of A sanguinicola from blood cultures were retrospectively identified from 2 clinical microbiology laboratories for 2006 to 2012. Species identity was confirmed through sequencing of the 16S rRNA gene. The medical charts of patients were reviewed. The minimum inhibitory concentration (MIC) for relevant antibiotics was determined. Biofilm formation was measured as the amount of crystal violet absorbed. Platelet aggregation was determined by aggregometry.
Eleven cases of A sanguinicola bacteremia were identified. All patients were male and the median age was 82 years (range 67-93). Nine patients fulfilled criteria for severe sepsis, and 2 patients died at hospital. Two patients were diagnosed with infective endocarditis. Most patients had underlying urinary tract diseases or an indwelling urinary tract catheter. Five patients suffered from dementia. None of the patients was treated with immunosuppressive medications. The MIC values of the isolates were in line with previous reports, with low MICs for penicillin, cefotaxime, and vancomycin. All 11 isolates produced biofilms but not all could induce platelet aggregation.
A sanguinicola can cause severe infections in elderly men with urinary tract abnormalities and the bacteria possess potential virulence mechanisms.
自 2001 年 Aerococcus sanguinicola 被指定为一个物种以来，仅有少数几例菌血症的报告。本研究的目的是描述 A. sanguinicola 菌血症的临床表现，并确定其抗生素敏感性以及形成生物膜和诱导血小板聚集的能力。
从 2006 年至 2012 年，我们在 2 个临床微生物学实验室中对血液培养物中分离出的 A. sanguinicola 进行了回顾性鉴定。通过 16S rRNA 基因测序来确认物种身份。对患者的病历进行了审查。测定了相关抗生素的最小抑菌浓度（MIC）。通过结晶紫吸收来测量生物膜形成。通过聚集仪测定血小板聚集。
共鉴定出 11 例 A. sanguinicola 菌血症。所有患者均为男性，中位年龄为 82 岁（范围 67-93 岁）。9 例患者符合严重脓毒症标准，2 例患者在医院死亡。2 例患者被诊断为感染性心内膜炎。大多数患者患有下尿路感染或留置导尿管。5 例患者患有痴呆。没有患者接受免疫抑制药物治疗。分离株的 MIC 值与之前的报告一致，对青霉素、头孢噻肟和万古霉素的 MIC 值较低。所有 11 株分离株均产生生物膜，但并非所有分离株都能诱导血小板聚集。
A. sanguinicola 可引起老年男性泌尿道异常的严重感染，且该细菌具有潜在的毒力机制。
